Clovis Oncology Inc. [CLVS] has traded in a range of $2.93 to $17.37 in the last 1 year. As of this writing, the stock is at $6.22, up 2.98%. To check whether the stock’s short-term amount has a thrust, its good to check stock’s recent movement. Over the last week, CLVS shares are 3.34% up with the monthly amount drift of -21.71% and seems bad in a long time frame.
On 17, September 2020, New Data Presented at ESMO Virtual Congress 2020 Highlight Breadth and Potential of Clovis Oncology Products and Pipeline. According to news published on Yahoo Finance, Initial data from the Phase 1b part of the LIO-1 trial of lucitanib combined with Opdivo® (nivolumab) in advanced metastatic solid tumors identify a recommended Phase 2 dose and show promising signs of antitumor activity.
Analyst Birdseye View:
The most recent analyst activity for Clovis Oncology Inc. [NASDAQ:CLVS] stock was on April 27, 2020, when it was Downgrade with an Underperform rating from SVB Leerink, which also raised its 12-month price target on the stock to $5. Before that, on May 18, 2020, H.C. Wainwright Recapitulated a Buy rating and elevated its amount target to $33. On April 09, 2020, BofA/Merrill Downgrade an Underperform rating and boosted its price target on this stock to $6. On January 08, 2020, H.C. Wainwright Reiterated a Buy rating and decreased its price target from $36 to $27. On November 19, 2019, Evercore ISI Downgrade an In-line rating and increased its price target to $8. On September 24, 2019, SVB Leerink Downgrade a Mkt perform rating and boosted its amount target on this stock to $10. On August 13, 2019, BofA/Merrill Downgrade a Neutral rating. Guggenheim elevated its amount target by recapitulating a higher weight for this stock.
In the past 52 weeks of trading, this stock has oscillated between a low of $2.93 and a peak of $17.37. Right now, according to Wall Street analyst the average 12-month amount target is $8.67. At the most recent market close, shares of Clovis Oncology Inc. [NASDAQ:CLVS] were valued at $6.22. According to the average price forecast, investors can expect a potential return of -50.0%.
Clovis Oncology Inc. [NASDAQ:CLVS] most recently reported quarterly sales of 39.89 billion, which represented growth of 20.90%. This publicly-traded organization’s revenue is $295,467 per employee, while its income is -$827,322 per employee. This company’s Gross Margin is currently 75.40%, its Pretax Margin is -278.75, and its Net Margin is -280.01.
The Principal structure of this organization shows its whole liability to whole principal at 132.25 and the whole liability to whole assets at 106.72. It shows enduring liability to the whole principal at 131.25 and enduring liability to assets at 1.06 while looking for an extended time period.
Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 5.86 points at 1st support level, the second support level is making up to 5.68. But as of 1st resistance point, this stock is sitting at 6.18 and at 6.32 for 2nd resistance point.
Clovis Oncology Inc. [CLVS] reported its earnings at -$1.15 per share in the fiscal quarter closing of 6/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$1.04/share signifying the difference of -0.11 and -10.60% surprise value. Comparing the previous quarter ending of 3/30/2020, the stated earnings were -$1.39 calling estimates for -$1.28/share with the difference of -0.11 depicting the surprise of -8.60%.
Important Ratio’s To Watch
Meanwhile, turning our focus to liquidity, the Current Ratio for Clovis Oncology Inc. [NASDAQ:CLVS] is 2.90. Likewise, the Quick ratio is also the same, showing Cash ratio at 2.23. Now if looking for a valuation of this stock’s amount to sales ratio it’s 3.93.
The most recent insider trade was by Rolfe Lindsey, See Remarks, and it was the sale of 1747.0 shares on Sep 21. IVERS-READ GILLIAN C, the See Remarks, completed a sale of 838.0 shares on Sep 21. On Sep 03, Gross Paul Edward, See Remarks, completed a sale of 435.0 shares.